Mouse Anti-MSLN Recombinant Antibody (clone MN) (CAT#: HPAB-1780-FY)

Figure 1 MSLN and MUC16 co-immunoprecipitate in pancreatic cancer cells.

Whole lysates from scramble control SW1990 cells were immunoprecipitated with either an anti-MUC16 or anti-MSLN or an isotype control antibody, and analyzed for MSLN or MUC16 reactivity by immunoblotting.

Chen, S. H., Hung, W. C., Wang, P., Paul, C., & Konstantopoulos, K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013; 3: 1870.

Figure 2 MSLN and MUC16 co-immunoprecipitate in pancreatic cancer cells.

Whole lysates from MUC16-KD SW1990 and Pa03C cells were immunoprecipitated with either an anti-MUC16 or anti-MSLN or an isotype control antibody, and analyzed for MSLN or MUC16 reactivity by immunoblotting.

Chen, S. H., Hung, W. C., Wang, P., Paul, C., & Konstantopoulos, K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013; 3: 1870.

Figure 3 MUC16 expression correlates with MSLN-mediated MMP-7 induction in pancreatic cancer cells.

MUC16, MSLN, and MMP-7 expression in pancreatic cancer tissue specimens was determined by immunohistochemical staining using an anti-MUC16, anti-MSLN, or anti-MMP-7 antibody, respectively.

Chen, S. H., Hung, W. C., Wang, P., Paul, C., & Konstantopoulos, K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013; 3: 1870.

Figure 4 MSLN immunohistochemistry in colon cancer tissue.

Case of tubular adenocarcinoma. Diffuse and luminal MSLN expression was detected.

Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., ... & Kasai, K. (2020). Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters, 19(3), 1741-1750.

Figure 5 Expression of MSLN in cultured colon cancer cells.

MSLN was expressed in four of seven colon cancer cell lines with no association with sex.

Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., ... & Kasai, K. (2020). Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters, 19(3), 1741-1750.

Figure 6 Forced‑expression of MSLN upregulates colon cancer cell proliferation.

Immunoblot analyses of CW‑2 and HCT‑116 cells with stable expression of MSLN or its control, LacZ.

Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., ... & Kasai, K. (2020). Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters, 19(3), 1741-1750.

Figure 7 MSLN knockdown downregulates colon cancer cell proliferation.

Immunoblot analyses of COLO205 and SW48 cells transfected with siRNAs.

Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., ... & Kasai, K. (2020). Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters, 19(3), 1741-1750.

Figure 8 MAbreactivity on ELISA coated with mesothelin-Fc.

ELISA plates were coated with mesothelin-Fc (2 μg/mL). Then, ELISA plates were incubated with anti-mesothelin MAbs, MN, MB, K1 or 5B2, followed by horseradish peroxidase-conjugated goat anti-mouse IgG.

Onda, M., Willingham, M., Nagata, S., Bera, T. K., Beers, R., Ho, M., ... & Pastan, I. (2005). New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clinical cancer research, 11(16), 5840-5846.

Figure 9 MAb reactivity on ELISA coated with bacterial maltose-binding protein-mesothelin.

ELISA plates were coated with bacterial mesothelin (2 μg/mL).Then, ELISA plates were incubated with anti-mesothelin MAbs, MN, MB, K1 or 5B2, followed by horseradish peroxidase-conjugated goat anti-mouse IgG.

Onda, M., Willingham, M., Nagata, S., Bera, T. K., Beers, R., Ho, M., ... & Pastan, I. (2005). New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clinical cancer research, 11(16), 5840-5846.

Figure 10 FACS analysis of anti-mesothelin MAbs with H226 cells.

Cells were incubated with the anti-mesothelin MAbs (1 μg/mL) or anti-CD30 MAbs,T6, as a negative control, followed by PE-labeled goat anti-mouse IgG.

Onda, M., Willingham, M., Nagata, S., Bera, T. K., Beers, R., Ho, M., ... & Pastan, I. (2005). New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clinical cancer research, 11(16), 5840-5846.